Advaxis, Inc. (ADXS)

Teaching the Immune System to Fight Cancer™

The Advaxis Lm TechnologyTM, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Clinical Pipeline

Clinical Pipeline

Visit Advaxis Clinical Pipeline for more information on axalimogene filolisbac (ADXS-HPV) Clinical Program for HPV-associated cancers.

View Clinical Pipeline

Industry Recognition

2015 EOY Regional Award Winner

Advaxis’s President and CEO was selected as a winner in the 2015 Ernst & Young (EY) Entrepreneur Of The Year® in New Jersey at a special event on June 25 at the Hyatt Regency in New Brunswick, N.J.

Learn More


More Information

Upcoming Event

SITC 2015

National Harbor, MD